Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• Lexicon Pharmaceuticals has received a consensus rating of "Moderate Buy" from six research firms, with three analysts rating it as a hold and three as a buy.
• The company's average 12-month target price is $3.2250, with HC Wainwright setting a target of $4.00 and Citigroup increasing theirs to $1.90.
• Lexicon reported earnings of $0.01 per share for the last quarter, exceeding expectations significantly, and had revenue of $28.87 million against a forecast of $4.87 million.

Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the six brokerages that are covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $3.2250.

A number of research firms have issued reports on LXRX. HC Wainwright reissued a "buy" rating and issued a $4.00 target price on shares of Lexicon Pharmaceuticals in a research report on Tuesday. Citigroup lifted their price target on Lexicon Pharmaceuticals from $1.20 to $1.90 and gave the stock a "buy" rating in a research note on Thursday, August 7th.

Lexicon Pharmaceuticals Trading Down 0.4%

Shares of Lexicon Pharmaceuticals stock traded down $0.01 on Friday, hitting $1.12. 193,798 shares of the company's stock traded hands, compared to its average volume of 8,254,878. Lexicon Pharmaceuticals has a one year low of $0.28 and a one year high of $2.18. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.16 and a quick ratio of 4.16. The company has a fifty day moving average of $1.09 and a two-hundred day moving average of $0.76. The company has a market capitalization of $405.19 million, a price-to-earnings ratio of -3.38 and a beta of 1.26.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.09. Lexicon Pharmaceuticals had a negative return on equity of 83.63% and a negative net margin of 206.43%.The business had revenue of $28.87 million for the quarter, compared to analyst estimates of $4.87 million. As a group, sell-side analysts expect that Lexicon Pharmaceuticals will post -0.66 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of LXRX. Invesco Ltd. increased its holdings in shares of Lexicon Pharmaceuticals by 60.6% in the fourth quarter. Invesco Ltd. now owns 104,494 shares of the biopharmaceutical company's stock worth $77,000 after buying an additional 39,420 shares during the period. Renaissance Technologies LLC purchased a new position in Lexicon Pharmaceuticals in the 4th quarter worth approximately $38,000. Barclays PLC increased its stake in Lexicon Pharmaceuticals by 25.5% in the 4th quarter. Barclays PLC now owns 243,316 shares of the biopharmaceutical company's stock worth $180,000 after purchasing an additional 49,443 shares during the period. Stifel Financial Corp increased its stake in Lexicon Pharmaceuticals by 117.0% in the 4th quarter. Stifel Financial Corp now owns 112,853 shares of the biopharmaceutical company's stock worth $83,000 after purchasing an additional 60,856 shares during the period. Finally, Boothbay Fund Management LLC purchased a new position in Lexicon Pharmaceuticals in the 4th quarter worth approximately $355,000. Hedge funds and other institutional investors own 74.70% of the company's stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.